Variant allele frequency: a decision-making tool in precision oncology?

Luca Boscolo Bielo1, Dario Trapani1, Matteo Repetto2

  • 1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Trends in Cancer
|September 13, 2023
PubMed
Summary

Variant allele frequency (VAF) shows promise as a predictive biomarker in precision oncology for selecting targeted therapies. Further validation is needed to standardize its clinical use.